OKYO Pharma Stock (NASDAQ:OKYO)
Previous Close
$1.07
52W Range
$0.81 - $2.12
50D Avg
$1.07
200D Avg
$1.27
Market Cap
$35.58M
Avg Vol (3M)
$78.00K
Beta
-3.36
Div Yield
-
OKYO Company Profile
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| CVKD | Cadrenal Therapeutics, Inc. Common Stock |
| PXMD | PaxMedica, Inc. Common Stock |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| HILS | Tharimmune, Inc. |
| CMND | Clearmind Medicine Inc. |
| VRAX | Virax Biolabs Group Limited |
| CADL | Candel Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |
| CDIO | Cardio Diagnostics Holdings, Inc. |